Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

APC

7 articles · Resources: NCBI Gene, OncoKB

Clinical · Bioinfo & AI

Computational screening of oncogenic genetic variations in tumor suppressor proteins driving gastric cancer pathogenesis

Mim FF, Sumiya TA, Khanam R, et al.

PloS one

This study employed a deep learning-based graph neural network model to identify genes and pathogenic genetic variations driving gastric cancer pathogenesis. Researchers focused on tumor suppressor proteins exhibiting both dysregulated expression and high mutation propensity. The model identified 1,886 relevant genes, with TP53, ERBB2, CDH1, and APC emerging as prominent hub genes. Missense and nonsense variants in TP53, CDH1, and APC were validated, affecting post-translational modification sites and correlating with altered patient survival. The study also highlighted EZH2 and miR-129-5p as key regulators and the dysregulation of oncogenes like CCNE1/2 and FGFR2.

Clinical · Molecular biology

Identification of Novel Pathogenic Variants in Familial Adenomatous Polyposis Through Whole Genome Sequencing

Choi SR, Kim MJ, Ku JL, et al.

Human mutation

This study investigated the use of whole genome sequencing (WGS) to identify pathogenic variants previously undetected by routine genetic testing in patients with unexplained familial adenomatous polyposis (FAP). Researchers discovered two novel APC gene variants: a large deletion encompassing exon 10 and a deep intronic complex deletion-insertion variant. These variants were validated at the transcript level, confirming their impact on splicing and leading to truncated protein production. The findings underscore the importance of WGS and RNA-based analysis for comprehensive genetic diagnosis of FAP.

Clinical · Molecular biology

Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype

Gantzer J, Lu X, Weingertner N, et al.

European journal of cancer (Oxford, England

This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.

Clinical · Molecular biology · Bioinfo & AI

Distinct Germline Mutation Landscape and Clinical Implications in Chinese Colorectal Cancer: A Large-Scale Genomic Analysis of 1094 Patients

Lu L, Peng X, Zhang J, et al.

Cancer medicine

This study investigated the prevalence and characteristics of germline mutations in 1094 Chinese colorectal cancer (CRC) patients using a 53-gene hereditary cancer panel. Pathogenic/likely pathogenic (P/LP) germline mutations were identified in 9.3% of patients, with mismatch repair (MMR) genes being the most frequently affected. Chinese patients showed lower frequencies of MUTYH and APC mutations but higher rates of MMR mutations compared to Western populations. Patients harboring germline P/LP mutations had significantly better progression-free survival, and a notable proportion of carriers lacked family history or were diagnosed after age 65. These findings highlight the need for population-specific genetic testing and screening strategies tailored for Asian populations.

Molecular biology

Ras-MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis

Venkatachalam N, Wang L, Muthukumarana N, et al.

Cell communication and signaling

This study demonstrates that MEK1/2 inhibitors, targeting the Ras-MAPK pathway, induce AXIN1 protein loss in colorectal cancer cell lines and patient-derived organoids. Unlike GSK3 inhibitors, this loss is not attributed to altered AXIN1 protein stability or post-translational modifications, nor to a significant reduction in its transcript levels. Analyses revealed that MEK1/2 inhibitors reduce global protein synthesis via an mTOR-associated pathway, an effect sufficient to cause AXIN1 loss. Co-treatment with tankyrase inhibitors was shown to partially prevent this AXIN1 reduction.

Clinical · Molecular biology

Gastric-Type Adenomas of the Nonampullary Duodenum: Reappraisal of Clinicopathological and Molecular Features and a Proposal for Novel Classification

Yamamoto H, Kawatoko S, Oshiro Y, et al.

The American journal of surgical pathology

This study re-evaluates the clinicopathological and molecular features of nonampullary duodenal neoplasms with gastric phenotype, proposing a novel classification. Analyzing 105 lesions, researchers observed a predominance of low-grade tumors and frequent heterogeneity. Next-generation sequencing revealed recurrent mutations in GNAS, KRAS, and APC. MDM2 gene amplification was identified as a potential marker for histological progression in high-grade tumors. Despite morphological diversity, the prognosis was extremely favorable, with no metastases, supporting the reclassification as "gastric-type adenomas."

Clinical · Molecular biology

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy

Oh CR, Lee JY, Kim JE, et al.

Clinical & translational oncology

This prospective observational study assessed the utility of circulating tumor DNA (ctDNA) for mutational profiling and dynamic monitoring in 33 patients with metastatic colorectal cancer receiving palliative chemotherapy. ctDNA was detected in most patients at baseline, revealing frequent mutations in APC, TP53, KRAS, and PIK3CA. Good concordance was observed between plasma ctDNA profiles and tissue data. Longitudinal analysis showed the emergence of acquired mutations, particularly RAS mutations under anti-EGFR therapy, and correlated high ctDNA levels with shorter overall survival. These findings highlight ctDNA’s potential to guide personalized treatment strategies and monitor resistance.